Ferring Pharmaceuticals: Ferring Presents New Analyses of Ef

New subgroup analyses presented at Digestive Disease Week (DDW) 2022 on the integrated efficacy results of Phase 2b and Phase 3 clinical studies of RBX2660. Data adds to the growing body

Related Keywords

Switzerland , United States , American , Kaplan Meier , Kostenloser Wertpapierhandel , Lisa Ellen , Paul Feuerstadt , Centers For Disease , Instagram , Us Centers For Disease , American Society For Gastrointestinal Endoscopy , Brand Communications , Linkedin , Twitter , Society For Surgery Of The Alimentary Tract , Ferring Pharmaceuticals , Drug Administration , Youtube , Facebook , Yale University School Of Medicine , American Gastroenterological Association , Digestive Disease Week , Clostridioides Difficile Infection , Subgroup Analysis , Yale University School , Treatment Success , Reducing Recurrent Clostridioides , Underlying Comorbidities , Charlson Comorbidity Index , Bile Acid Restoration , Consistent Across Three Clinical Trials , Recurrent Clostridioides Difficile Infection , Combined Analysis , Infection Treated , Disease Control , Fast Track , Breakthrough Therapy , Disease Week , American Association , Liver Diseases , American Society , Gastrointestinal Endoscopy , Alimentary Tract , Biggest Threats , Dis Clin North , Manag Care Spec , Clin Microbiol , Rev Dis , Spreferring , Pharmaceuticals , Presents , Analyses , Efficacy , Safety , Icrobiome , Composition , Data , 022 , Bx2660 , Investigational , Microbiota , Ased , Five , Biotherapeutic ,